Profusa and Mayo Clinic Advance CLTI Treatment With Real-Time Tissue Oxygen Monitoring

Profusa, Inc. (PFSA) has unveiled a strategic partnership with Mayo Clinic to revolutionize how physicians monitor tissue oxygen levels in chronic limb-threatening ischemia (CLTI) and other life-altering conditions. The collaboration centers on the Lumee platform, a tissue-embedded biosensor system designed to provide continuous, real-time measurement of oxygen saturation directly within the body—marking a significant departure from traditional surface-level monitoring approaches.

Technology Foundation: Over a Decade of Development in Tissue-Integrated Sensing

The Lumee platform represents the culmination of more than ten years of research and development, supported by over $100 million in cumulative investment. According to Ben Hwang, Ph.D., Chairman and CEO of Profusa, this breakthrough technology enables physicians to detect oxygen deficits at the tissue level with unprecedented precision and continuity. Unlike conventional monitoring systems that rely on external measurements, Lumee’s tissue-integrated design allows for intra-organ perfusion assessment—critical for detecting early warning signs of complications.

Clinical Applications: From CLTI to Multi-System Impact

The Mayo Clinic partnership will systematically evaluate Lumee’s potential across cardiovascular, renal, multi-organ, and orthopedic patient populations. CLTI represents a particularly compelling application, as chronic limb ischemia currently affects millions globally and remains a leading cause of lower-extremity amputation. Michael Kendrick, M.D., Chair of the Department of Surgery at Mayo Clinic, emphasized that tissue oxygen deficits directly contribute to impaired wound healing, heightened infection risk, and post-operative complications. He noted that “the collaboration provides an opportunity to leverage this platform to address unmet clinical challenges, including monitoring beyond subcutaneous tissue.”

Commercialization Pathway: Accelerating Regulatory and Market Entry

The partnership is specifically designed to fast-track U.S. commercialization of the Lumee platform for CLTI management. Mayo Clinic maintains a financial interest in the technology and will channel any revenue from its utilization back into its patient care, education, and research initiatives. This structure aligns clinical innovation with broader healthcare impact, ensuring the technology serves the greatest therapeutic need.

Market Dynamics: Recent Corporate Actions and Stock Performance

Profusa recently executed a 1-for-75 reverse stock split, completed on February 9, 2026, as part of broader capital management strategy. As of early March 2026, PFSA shares traded at $2.72, reflecting a 9.93% decline from recent levels. This consolidation, combined with the Mayo Clinic collaboration announcement, positions the company at an inflection point between research validation and commercial deployment.